OCS

Oculis Holding AG Ordinary shares

24.94

USD

OCS Earnings Reports

Positive Surprise Ratio

OCS beat 4 of 12 last estimates.

33%

Next Report

Date of Next Report

May 07, 2026

Estimate for Q1 26 (Revenue/ EPS)

$198.17K

-$0.41

Implied change from Q4 25 (Revenue/ EPS)

-51.78%

-2.38%

Implied change from Q1 25 (Revenue/ EPS)

-30.47%

-40.58%

Oculis Holding AG Ordinary shares earnings per share and revenue

On Mar 03, 2026, OCS reported earnings of -0.42 USD per share (EPS) for Q4 25, beating the estimate of -0.42 USD, resulting in a 1.62% surprise. Revenue reached 411.00 thousand, compared to an expected 132.46 thousand, with a 210.28% difference. The market reacted with a +0.54% price change (close before vs. close after earnings).

Looking ahead to Q1 26, 6 analysts forecast an EPS of -0.41 USD, with revenue projected to reach 198.17 thousand USD, implying an decrease of -2.38% EPS, and decrease of -51.78% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Precigen, Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.08

Actual

-$0.01

Surprise

+88.24%

Absci Corporation Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.19

Actual

-$0.23

Surprise

-16.04%

Candel Therapeutics, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.25

Actual

-$0.54

Surprise

-115.31%

LENZ Therapeutics, Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.99

Actual

-$1.15

Surprise

-17.10%

Fennec Pharmaceuticals Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

$0.03

Actual

-$0.11

Surprise

-408.12%

Equillium, Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.06

Actual

-$0.04

Surprise

+35.28%

MaxCyte, Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.08

Actual

-$0.06

Surprise

+26.47%

Celcuity Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$1.06

Actual

-$0.97

Surprise

+8.72%

TELA Bio, Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.18

Actual

-$0.16

Surprise

+14.12%

Dyadic International, Inc.

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.04

Actual

-$0.06

Surprise

-30.72%

FAQ

What were Oculis Holding AG Ordinary shares's earnings and revenue for the latest quarter Q4 2025?

For Q4 2025, Oculis Holding AG Ordinary shares reported EPS of -$0.42, beating estimates by 1.62%, and revenue of $411.00K, 210.28% above expectations.

How did the market react to Oculis Holding AG Ordinary shares's Q4 2025 earnings?

The stock price moved up 0.54%, changed from $27.57 before the earnings release to $27.72 the day after.

When is Oculis Holding AG Ordinary shares expected to report next?

The next earning report is scheduled for May 07, 2026.

What are the forecasts for Oculis Holding AG Ordinary shares's next earnings report?

Based on 6 analysts, Oculis Holding AG Ordinary shares is expected to report EPS of -$0.41 and revenue of $198.17K for Q1 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.